Mouse myeloma cell line secreting bifunctional fusion protein RM4/IFN- τ elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo

Journal of Interferon and Cytokine Research

Volumn 16, Issue 10, 1996, Pages 771-776

  Qi, Yumin ^a   Chen, Yue ^b   Xiang, Jim ^a,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c Saskatoon Cancer Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERFERON; TAU INTERFERON;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELLULAR IMMUNITY; CHROMIUM 51 RELEASE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; LYMPHOCYTE DEPLETION; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0029909453     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1996.16.771     Document Type: Article

References (37)

1. ROS, F., COCHET, M., and FELLOUS, M. (1986). Interferon and major histocompatibility complex genes: a model to analyze eukaryotic gene regulation. In: Interferon-τ I. Gresser (ed.) London: Academic, pp. 47-87.
2. SCHWARTZ, R., MOMBURG, F., MOLDENHAUER, G., DORKEN, B., and SCHIRRMACHER, V. (1985). Induction of HLA class II antigen expression on human carcinoma cell lines by IFN-τ. Int. J. Cancer 35, 245-252.
3. FADY, C., GARDNER, A., GERA, J., and LICHTENSTEIN, A. (1992). Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: selective effects on HER2/neu expressing cells. Cancer Res. 52, 764-769.
4. TANAKA, K., ISSELBACHER, K., KHOURY, G., and JAY, G. (1985). Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 228, 26-29.
5. GREINER, J., GUADAGNI, F., NOGUCHI, P., PESTKA, S., COLCHER, D., FISHER, P., and SCHLOM, J. (1987). Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 235, 895-898.
6. KANTOR, J., TRAN, R., GREINER, J., PESTKA, S., FISHER, P., SHIVELY, J., and SCHLOM, J. (1989). Modulation of carcinoembryonic antigen messenger RNA levels in human colon carcinoma cells by recombinant human τ-interferon. Cancer Res. 49, 2651-2655.
7. ADAMS, D., and HAMILYON, T. (1987). Molecular transduction mechanisms by which IFN-gamma and other signals regulate macrophage development. Immunol. Rev. 97, 5-19.
8. WEIGENT, D., STANTON, J., and JOHNSON, H. (1983). Recombinant gamma Interferon. Biochem. Biophys. Res. Commun. 111, 525-529.
9. SONE, S., UTSUGI, T., and OGURA, T. (1988). Differential effects of recombinant interferon alpha, beta and gamma on induction of human lymphokine-activated killer activity. J. Natl. Cancer Inst. 80, 425-431.
10. LANDOLF, S., GARIGLIO, M., GRIBAUDO, G., JEMMA, C., GIOVARELLI, M., and CAVALLO, G. (1988). Interferon-gamma is not an antiviral but a growth-promoting factor for T lymphocytes. Eur. J. Immunol. 18, 503-509.
11. MARASKOVSKY, E., CHEN, W., and SHORTMAN, K. (1989). IL-2 and IFN-τ are two necessary lymphokines in the development of cytolytic T cells. J. Immunol. 143, 1210-1214.
12. FIDLER, J. (1980). Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science 208, 1469-1471.
13. DE GRAAF, P., HORAK, E., and BOOKMAN, M. (1988). Adoptive immunotherapy of syngeneic murine leukemia is enhanced by the combination of recombinant IFN-τ and a tumor-specific cytotoxic T cell clone. J. Immunol. 140, 2853-2857.
14. MALIK, S., KNOWLES, R., EAST, N., LANDO, D., STAMP, G., and BALKWILL, F. Antitumor activity of τ-interferon in ascites and solid tumor models of human ovarian cancer. Cancer Res. 51, 6643-6649.
15. ERNSTOFF, M., GOODING, W., NAIR, S., BAHNSON, R., MIKKETIC, L., BANNER, B., DAY, R., WHITESIDE, T., and KIRKWOOD, J. (1992). Immunological effects of treatment with sequential administration of recombinant interferon-τ and alpha in patients with metastases renal cell carcinoma during a phase I trial. Cancer Res. 52, 851-856.
16. PONZONI, M., CASALARO, A., LANCIOTTI, M., MONTALDO, F., and CORNAGLIA-FERRARIS, P. (1992). The combination of τ-interferon and tumor necrosis factor causes a rapid and extensive differentiation of human neuroblastoma cells. Cancer Res. 52, 931-939.
17. QUESADA, J., EVANS, L., SAKS, S., and GUTTERMAN, J. (1988). Recombinant interferon alpha and gamma in combinations as treatment for metastatic renal cell carcinoma. J. Biol. Resp. Modif. 7, 234-239.
18. KURZROCK, R., ROSENBLUM, M., and SHERWIN, S. (1985). Pharmacokinetics, single dose tolerance and biological activity of recombinant gamma interferon in cancer patients. Cancer Res. 45, 2866-2871.
19. FITZGERALD, D., WILLINGHAM, M., CARDARELLI, C., HAMADA, H., TSURUO, T., GOTTESMAN, M., and PASTAN, I. (1987). A monoclonal antibody-pseudomonas toxin conjugate that specifically kills multi-drug resistant cells. Proc. Natl. Acad. Sci. USA 84, 4288-4292.
20. HARVEN, E., FRADET, Y., CONNOLLY, J., HANA, W., HE, S., WANG, Y., CHOI, B., McGROARTY, R., BOOTSMA, G., TILUP, A., and CHRISTENSEN, H. (1992). Antibody drug carrier for immunotherapy of superficial bladder cancer. Ultrastructural studies. Cancer Res. 52, 3131-3137.
21. SCHMIDBERGER, H., BUCHSBAUM, D., BLAZAR, B., EVERSON, P., and VALLERA, D. (1991). Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of the T cell lymphoma EL4. Cancer Res. 51, 1883-1890.
22. SCHLOM, J., EGGENSPERGER, D., COLCHER, D., MOLINOLO, A., HOUCHENS, D., MILLER, L., HINKLE, G., and SILER, K. (1992). Therapeutic advantage of high affinity anticarcinoma radioimmunoconjugates. Cancer Res. 52, 1067-1072.
23. HOOGENBOOM, H., VOLCKAERT, G., and RAUS, J. (1991). Construction and expression of antibody-tumor necrosis factor fusion protein. Mol. Immunol. 28, 1027-1037.
24. XIANG, J., QI, Y., and MOYANA, T. (1996). Targeting gamma interferon to tumor cells by a genetically engineered bifunctional fusion protein RM4/TFN-τ. Hum. Antibodies Hybridomas. In press.
25. XIANG, J., MOYANA, T., KAIRA, J., HAMILTON, T., and QI, Y. (1992). Construction and characterization of a high-affinity chimeric anti-colorcctal carcinoma antibody ccM4. Mol. Biother. 4, 174-182.
26. PHILIP, F., SARA, R., and SIDNEY, P. (1981). A convenient and rapid cytopathic effect inhibition assay for interferon. Methods Enzymol. 78, 387-394.
27. CHEN, L., ASHE, S., BRADY, W., HELLSTROM, I., HELLSTROM, K., LEDBETTER, J., McGOWAN, P., and LINSLEY, P. (1992). Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecule CD28 and CTLA-4. Cell 71, 1093-1102.
28. NORUSIS, M. (1993). Statistical Package of Social Science for Windows. Base System User's Guide. Release 6.0, Chicago, IL: SPSS Inc.
29. SPITALNY, G., and HAVELL, E. (1984). Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. J. Exp. Med. 159, 1560-1565.
30. CHEN, L., MIZUNO, M., SINGHAL, M., HU, S., GALLOWAY, D., HELLSTROM, I., and HELLSTROM, K. (1992). Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J. Immunol. 148, 2617-2621.
31. GANSBACHER, B., BANNERJI, R., DANIELS, B., ZIER, K., CRONIN, K., and GILBOA, E. (1990). Retroviral vector-mediated τ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50, 7820-7825.
32. WATANABE, Y., KURIBAYASHI, K., MIYATAKE, S., NISHIHARA, K., NAKAYAMA, E., TANIYAMA, T., and SAKATA, T. (1989). Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity. Proc. Natl. Acad. Sci. USA 86, 9456-9460.
33. RESTIFO, N., SPIESS, P., KARP, S., MULE, J., and ROSENBERG, S. (1992). A nonimmunogenic sarcoma transduced with the cDNA for interferon elicits CD8 T cells against the wild-type tumor: correlation with antigen presentation capability. J. Exp. Med. 175, 1423-1431.
34. HOCK, H., DORSCH, M., KUNZENDORF, U., QIN, Z., DIAMANTSTEIN, T., and BLANKENSTEIN, T. (1993). Mechanisms of rejection induced by tumor cell targeted gene transfer of IL-2, IL-4, IL-7, TNF and IFN-τ. Proc. Natl. Acad. Sci. USA 90, 2774-2778.
35. ESUMI, N., HUNT, B., ITAYA, T., and FROST, P. (1991). Reduced tumorigenicity of murine tumor cells secreting IFN-τ is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. Cancer Res. 51, 1185-1189.
36. PORGADOR, A., BENNERJI, R., WATANABE, Y., FELDMAN, M., GILBOA, E., and EISENBACH, L. (1993). Antimetastatic vaccination of tumor-bearing mice with two types of IFN-τ gene-inserted tumor cells. J. Immunol. 150, 1458-1470.
37. KIMURA, A., and XIANG, J. (1986). High levels of Met-72 antigen expression: correlation with metastatic activity of B16 melanoma tumor cell variants. J. Natl. Cancer Inst. 76, 1247-1253.